Pharmacoproteomics in cardiac hypertrophy and atherosclerosis

Cardiovascular and Hematological Disorders - Drug Targets

Volumn 9, Issue 2, 2009, Pages 141-148

  Lazaro, Alberto ^a   Alvarez Llamas, Gloria ^b   Gallego, Julio ^a   de la Cuesta, Fernando ^b   Osende, Julio ^a   Eugenia, Ma E G ^c   Vivanco, Fernando ^b,d  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b Jimenez Diaz Foundation   (Spain)

^c National Paraplegics Hospital   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Atherosclerosis; Cardiac hyertrophy; Pharmacoproteomics; Proteomics

Indexed keywords

ALPHA ENOLASE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; CALCIUM ANTAGONIST; CALSARCIN 1; CARVEDILOL; CATHEPSIN D; CELL PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; ENALAPRIL; FOSINOPRIL; GALAPTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOW DENSITY LIPOPROTEIN; MULTIENZYME COMPLEX; PHOSPHOGLYCERATE KINASE; PROTEIN KINASE C; PROTEIN KINASE C EPSILON; QUINAPRIL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE 1 ALPHA SUBCOMPLEX 10 LIKE PROTEIN; UNCLASSIFIED DRUG;

ABDOMINAL AORTA ANEURYSM; ANTIHYPERTENSIVE THERAPY; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; ENERGY METABOLISM; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE OVERLOAD; HEART PROTECTION; HUMAN; HYPERCHOLESTEROLEMIA; MOLECULAR DYNAMICS; NONHUMAN; OXIDATIVE STRESS; PHARMACOPROTEOMICS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS;

ANTIHYPERTENSIVE AGENTS; ATHEROSCLEROSIS; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTROPHY, LEFT VENTRICULAR; MYOCARDIUM; PROTEOME; PROTEOMICS;

EID: 68349107080     PISSN: 1871529X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152909788488672     Document Type: Article

References (45)

1. Whelton, P.K. Epidemiology of hypertension. Lancet, 1994, 344, 101-106.
2. Lackland, D.T. Systemic hypertension: an endemic, epidemic, and a pandemic. Semin. Nephrol., 2005, 25, 194-197.
3. Levy, D. Drugs. Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. 1988, 35 (Suppl 5), 1.
4. Mosterd, A.; Cost, B.; Hoes, A.W.; de Bruijne, M.C.; Deckers, J.W.; Hofman, A.; Grobbee, D.E. The prognosis of heart failure in the general population: The Rotterdam Study. Eur. Heart J., 2001, 22, 1318-1327.
5. Lips, D.J.; deWindt, L.J.; van Kraaij, D.J.; Doevendans, P.A. Molecular determinants of myocardial hypertrophy and failure: alternative pathways for beneficial and maladaptive hypertrophy. Eur. Heart J., 2003, 24, 883-896.
6. Lorell, B.H.; Carabello, B.A. Left ventricular hypertrophy: pathogenesis, detection and prognosis. Circulation, 2000, 102, 470-479.
7. Roman M.J.; Pickering T.G.; Schwartz J.E.; Pini R.; Devereux R.B. Association of carotid atherosclerosis and left ventricular hypertrophy. JACC, 1995, 25, 83.
8. Okin P.M.; Devereux R.B.; Kligfield P. Association of carotid atherosclerosis with electrocardiographic myocardial ischemia and left ventricular hypertrophy. Hypertension, 1996, 28, 3-7.
9. Kronmal R.A.; Smith V.E.; O'Leary D.H.; Polak J.F.; Gardin J.M.; Manolio T.A. Carotid artery measures are strongly associated with left ventricular mass in older adults (a report from the Cardiovascular Health Study). Am. J. Cardiol., 1996, 77, 628-633.
10. Rader D.J.; Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature, 2008, 451, 904-913.
11. Vivanco F.; Mas S.; Darde V.M.; de la Cuesta F.; Alvarez-Llamas G.; Barderas M.G. Vascular Proteomics. Proteomics Clin. Appl., 2007, 1, 1102.
12. Rapundalo, S. T. In Proteomic and Genomic Analysis of Cardiovascular Disease; Van Eyk J.E.; Dunn M.J., Eds.; Wiley-VCH: Weinheim, 2003; pp. 359.
13. Klingbeil, A.U.; Schneider, M.; Martus, P.; Messerli, F.H.; Schmieder, RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med., 2003, 115, 41-46.
14. Franco, V.; Oparil, S.; Carretero, O.A. Hypertensive therapy: Part II. Circulation, 2004, 109, 3081.
15. Faber, M.J.; Agnetti, G.; Bezstarosti, K.; Lankhuizen, I.M.; Dalinghaus, M.; Guarnieri, C.; Caldarera, C.M.; Helbing, W.A.; Lamers, J.M. Recent developments in proteomics: implications for the study of cardiac hypertrophy and failure. Cell Biochem. Biophys., 2006, 44, 11.
16. Mayr, M.; Zhang, J.; Greene, A.S.; Gutterman, D.; Perloff, J.; Ping, P. Proteomics-based development of biomarkers in cardiovascular disease: mechanistic, clinical, and therapeutic insights. Mol. Cell Proteomics, 2006, 5, 1853.
17. Zhou, S.G.; Zhou, S.F.; Huang, H.Q.; Chen, J.W.; Huang, M.; Liu, P.Q. Proteomic analysis of hypertrophied myocardial protein patterns in renovascularly hypertensive and spontaneously hypertensive rats. J. Proteome Res., 2006, 5, 2901.
18. Casey, T.M.; Arthur, P.G.; Bogoyevitch, M.A. Proteomic analysis reveals different protein changes during endothelin-1- or leukemic inhibitory factor-induced hypertrophy of cardiomyocytes in vitro. Mol. Cell Proteomics, 2005, 4, 651.
19. Lindsey, M.L.; Goshorn, D.K.; Comte-Walters, S.; Hendrick, J.W.; Hapke, E.; Zile, M.R.; Schey, K. A multidimensional proteomic approach to identify hypertrophy-associated proteins. Proteomics, 2006, 6, 2225.
20. Arnott, D.; O'Connell, K.L.; King, K.L.; Stults, J.T. An integrated approach to proteome analysis: identification of proteins associated with cardiac hypertrophy. Anal. Biochem., 1998, 258, 1.
21. Bupha-Intr, T.; Holmes, J.W.; Janssen, P.M. Induction of hypertrophy in vitro by mechanical loading in adult rabbit myocardium. Am. J. Physiol. Heart Circ. Physiol., 2007, 293, H3759.
22. Faber, M.J.; Dalinghaus, M.; Lankhuizen, I.M.; Bezstarosti, K.; Dekkers, D.H.; Duncker, D.J.; Helbing, W.A.; Lamers, J.M. Proteomic changes in the pressure overloaded right ventricle after 6 weeks in young rats: correlations with the degree of hypertrophy. Proteomics, 2005, 5, 2519.
23. Devereux, R.B.; Dahlof, B.; Gerdts, E.; Boman, K.; Nieminen, M.S.; Papademetriou, V.; Rokkedal, J.; Harris, K.E.; Edelman, J.M.; Wachtell, K. Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial. Circulation, 2004, 10, 1456.
24. Gallego-Delgado, J.; Lazaro, A.; Osende, J.I.; Barderas, MG.; Blanco-Colio, L.M.; Duran, M.C.; Martin-Ventura, J.L.; Vivanco, F.; Egido, J. Proteomic approach in the search of new cardiovascular biomarkers. Kidney Int. Suppl., 2005, 99, S103.
25. Roba, J.L. The use of spontaneously hypertensive rats for the study of anti-hypertensive agents. Lab. Anim. Sci., 1976, 26, 305.
26. Lazaro, A.; Gallego-Delgado, J.; Osende, J.I.; Egido, J.; Vivanco, F. Analysis of antihypertensive drugs in the heart of animal models: a proteomic approach. Methods Mol. Biol., 2007, 357, 45.
27. Gallego-Delgado, J.; Lazaro, A.; Osende, J.I.; Barderas, MG.; Duran, M.C.; Vivanco, F.; Egido, J. Comparison of the protein profile of established and regressed hypertension-induced left ventricular hypertrophy. J. Proteome Res. 2006, 5, 404.
28. Jin, X.; Xia, L.; Wang, L.S.; Shi, J.Z.; Zheng, Y.; Chen, W.L.; Zhang, L.; Liu, Z. G.; Chen, G.Q.; Fang, N.Y. Differential protein expression in hypertrophic heart with and without hypertension in spontaneously hypertensive rats. Proteomics, 2006, 6, 1948.
29. Allard, M.F. Energy substrate metabolism in cardiac hypertriophy. Curr. Hypertens. Rep., 2004, 6, 430.
30. Gallego-Delgado, J.; Lazaro, A.; Osende, J.I.; Esteban, V.; Barderas, M.G.; Gomez-Guerrero, C.; Vega, R.; Vivanco, F.; Egido, J. Proteomic analysis of early left ventricular hypertrophy secondary to hypertension: modulation by antihypertensive therapies. J. Am. Soc. Nephrol., 2006, 17, S159.
31. Inagaki, K.; Iwanaga, Y.; Sarai, N.; Onozawa, Y.; Takenaka, H.; Mochly-Rosen, D.; Kihara, Y. Tissue angiotensin II during progression or ventricular hypertrophy to heart failure in hypertensive rats; differential effects on PKC epsilon and PKC beta. J. Mol. Cell Cardiol., 2002, 34, 1377.
32. Dorn, G.W.; Force, T. Protein kinase cascades in the regulation of cardiac hypertrophy. J. Clin. Invest., 2005, 115, 527.
33. He, H.; Wang, W.; Zhang, H.; Ma, L.; Wu, H.; Wang, P.; Gao, J. Fosinopril and carvedilol reverse hypertrophy and change the levels of protein kinase C epsilon and components of its signaling complex. Cardiovasc. Drugs Ther., 2006, 20, 259.
34. Blanco-Colio L.M.; Tuñon J.; Martin-Ventura J.L.; Egido J. Antiinflammatory and immunomodulatory effects of statins. Kidney Int., 2003, 63, 12-23.
35. Almuti K.; Rimawi R.; Spevack D.; Ostfeld R.J. Effects of statins beyond lipid lowering: potential for clinical benefits. Int. J. Cardiol., 2006, 109, 7-15.
36. Shiraya S.; Miyake T.; Auki M.; Yoshikazu F.; OUI S.; Nishimura M.; Ogihara T.; Morishita R. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis, 2009, 202(1), 34-40.
37. Jukema J.W.; Zwinderman A.H.; van Boven A.J.; Reiber J.H.C.; van der Laarse A.; Lie K.I.; Bruschke AVG. Evidence for a synergistic effect of calcium channel blockers with lipid-lowering therapy in retarding progression of coronary atherosclerosis in symptomatic patients with normal to moderately raised cholesterol levels. The REGRESS Study Group. Arterioscler. Thromb. Vasc. Biol., 1996, 16, 425.
38. Trion A.; de Maat M.; Jukema W.; Maas A.; Offerman E.; Havekes L.; Szalai A.; van der Laarse A.; Princen H.; Emeis J. Antiatherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice. J. Cardiovasc. Pharmacol., 2006, 47, 89.
39. Delsing D.J.; Jukema J.W.; van de Wiel M.A.; Emeis J.J.; van der Laarse A.; Havekes L.M.; Princen H.M.G. Differential effects of amlodipine and atorvastatin treatment and their combination on atherosclerosis in ApoE*3-Leiden transgenic mice. J. Cardiovasc. Pharmacol., 2003, 42, 63.
40. Duran M.C.; Mas S.; Martin-Ventura J.L.; Meilhac O.; Michel J.B.; Gallego-Delgado J.; Lazaro A.; Tuñón J.; Egido J.; Vivanco F. Proteomic analysis of human vessels: application to atherosclerotic plaques. Proteomics, 2003, 3, 973.
41. Martin-Ventura J.L.; Tuñon J.; Duran M.C.; Blanco-Colio L.M.; Vivanco F.; Egido J. Vascular protection of dual therapy (atorvastatin-amlodipine) in hypertensive patients. J. Am. Soc. Nephrol., 2006, 17, S189.
42. Duran M.C.; Martin-Ventura J.L.; Mohammed S.; Barderas M.G.; Blanco-Colio L.M.; Mas S.; Moral V.; Ortega L.; Tuñon J.; Jensen O.N.; Vivanco F.; Egido J. Atorvastatin modulates the profile of proteins released by human atherosclerotic plaques. Eur. J. Pharmacol., 2007, 562, 119.
43. Cannon C.P.; Braunwald E.; McCabe C.H.; Rader D.J.; Rouleau J.L.; Belder R.; Joyal S.V.; Hill K.A.; Pfeffer M.A.; Skene A.M. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med., 2004, 350, 1495.
44. Gonzalez-Barderas M.; Gallego-Delgado J.; Mas S.; Duran M.C.; Lazaro A.; Hernandez-Merida S.; Egido J.; Vivanco F. Isolation of circulating human monocytes with high purity for proteomic analysis. Proteomics, 2004, 4, 432.
45. Barderas M.G.; Tuñon J.; Darde V.M.; de la Cuesta F.; Jimenez-Nacher J.J.; Tarin N.; Lopez-Bescos L.; Egido J.; Vivanco F. Atorvastatin modifies the protein profile of circulating human monocytes after an acute coronary síndrome. Proteomics, 2008, in press.